Irritable bowel syndrome therapy in Vietnam with probiotic enterococci

In this work, we compared composition of the intestinal microbiota of healthy volunteers and patients with irritable bowel syndrome (IBS) in Hanoi residents before and after therapy with a probiotic starter culture based on the bacteriocinogenic strain Enterococcus faecium L3 (L3), which is successfully used to correct dysbiosis and treat IBS in Russia.
In IBS patients (IBS group) α-diversity was higher than in the control group (Healthy) and in IBS patients after probiotic therapy (IBS + L3 group). Phylogenetic analysis of the studied samples refl ected the division of the studied communities into 2 clusters, one of which grouped samples, mainly taken for IBS before therapy. Principal component analysis (PCoA) showed that most of the samples from the IBS group are located on the graph in a separate sector, far from the adjacent IBS + L3 and Нealthy samples.
A study of the microbiome of Vietnamese patients with IBS after taking probiotic at the level of types (phyls) revealed a tendency towards an increase in the representation of Firmicutes. The introduction of L3 led to an increase in the population of members of the family Lachnospiraceae, such as butyrate- producing Roseburia and acetate-producing Blautia. At the same time, the percentage of staphylococci and bacteria belonging to the Enterobacteriaceae family was decreased. In addition to positive changes in the functioning of the gastrointestinal tract, revealed on the basis of clinical data, the features of the intestinal microbiota of IBS residents of Hanoi compared with healthy volunteers and in the same patients after probiotic therapy were revealed by metagenomic analysis of 16S rRNA genes. Positive shifts in the intestinal microbiome of IBS patients in Vietnam after therapy with a probiotic starter culture based on L3 do not fundamentally diff er from the previously described eff ects noted by the authors when using this probiotic in Russia, which creates the preconditions for expanding the possibility of its use in the Asian region.

1. Solov’eva O.I., Simanenkov V. I., Suvorov A. N., Ermolenko E. I., Shumihina I. A., Svirido D. A. The use of probiotics and autoprobiotics in the treatment of irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2017;(7):115–120. (In Russ.)

2. Ivashkin V.T., Shelygin Ju.A., Baranskaja E. K., et al. Russian Journal of Gastroenterology, Hepatology, Coloproctology. Clinical guidelines for the diagnosis and treatment of patients with irritable bowel syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014; 24(2):92–101. (In Russ.)

3. Xiong L. S., Chen M. H., Chen H. X., Xu A. G., Wang W. A., Hu P. J. A population-based epidemiologic study of irritable bowel syndrome in South China: stratifi ed randomized study by cluster sampling. Aliment. Pharmacol. Ther. 2004. Vol.19, pp.1217–1224. doi:10.1111/j.1365–2036.2004.01939.

4. Chey W. D., Kurlander J., Eswaran, S. Irritable bowel syndrome: aclinical review. JAMA. 2015. Vol. 313, pp.949–958. doi:10.1001/jama.2015.0954.

5. Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome. Front. Microbiol. 2018. Vol. 25; 9:1600. doi:10.3389/fmicb.2018.01600. eCollection 2018.

6. Quigley E. M., Fried M., Gwee K. A., et al.; Review Team:. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016; 50(9):704–13. doi:10.1097/MCG.0000000000000653.

7. Liu H. N., Wu H., Chen Y. Z., Chen Y. J., Shen X. Z., Liu T. T. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017; 49(4):331–337. doi:10.1016/j.dld.2017.01.142.

8. Ermolenko E. I., Bui T. L.A., Karaseva A. B., et al. Characteristics of enterococci isolated from the intestines of residents of Vietnam and Russia with irritable bowel syndrome. Gastroenterology of St. Petersburg. 2017, vol. 153, pp. 78–79. (In Russ.)

9. Ermolenko E. I., Kudryavtsev I. V., Solovyova O. I., et al. Profile of subpopulation composition of regulatory T lymphocytes and intestinal microbiota in patients with irritable bowel syndrome. Medical Immunology (Russia). 2020; 22(2):335–346. doi:10.15789/1563–0625-POS-1905.

10. Lee B. J., Bak Y. T. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011; 17(3): 252–66. doi:10.5056/jnm.2011.17.3.252.

11. Ford A. C., Harris L. A., Lacy B. E., Quigley E. M. M., Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018; 48(10):1044–1060. doi:10.1111/apt.15001.

12. Kim H. J., Vazquez Roque M. I., Camilleri M., Stephens D., Burton D. D., Baxter K., Thomforde G., Zinsmeister A. R. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005; 17(5):687–96. doi:10.1111/j.1365–2982.2005.00695.x.

13. Simrén M., Ohman L., Olsson J., Svensson U., Ohlson K., Posserud I., Strid H. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010; 31(2):218–27. doi:10.1111/j.1365–2036.2009.04183.x.

14. Suvorov A. What Is Wrong with Enterococcal Probiotics? Probiotics Antimicrob Proteins. 2020; 12(1):1–4. doi:10.1007/s12602–020–09633-y.

15. Suvorov А., Ermolenko E., Alechina G., Chernysh A., Karaseva A., Pierro F. Di. Enterococcus as probiotics: what is the advantage? Nutrafoods. 2019; 1:17–25. doi:10.17470/NF-019–0003.

16. DeSantis T.Z., Hugenholtz Р., Larsen N., et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006; 72(7):5069–72. doi:10.1128/AEM.03006–05.

17. McMurdie P.J., Holmes S. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013; 22; 8(4): e61217. doi:10.1371/journal.pone.0061217.

18. Alekhina G. G., Suvorov А. N. Enterococcus strain Entero coccus faecium l-3 for preparing curativeprophylactic agents and foodstuffs of curativeprophylactic designation. Patent № 2220199, 2002. (In Russ.)

19. Ermolenko E. I., Svirido D. A., Kotyleva M. P., Karaseva A. B., Simanenkov V. I., Suvorov A. N. Usage of indigenous enterococcus for the experimental irritable bowel syndrome treatment. [International Human Microbiome Consortium Congress]. Kaunas, 2016.

20. Abdurasulova I. N., Matsulevich A. V., Tarasova E. A., et al. Enterococcus faecium strain L-3 and glatiramer acetate ameliorate experimental allergic encephalomyelitis in rats by affecting different populations of immune cells. Benef Microbes. 2016; 7(5):719–729. doi:10.3920/BM2016.0018.

21. Miliukhina I., Ermolenko E., Ivanova A., Kotyleva M., Suvorov A. Probiotic correction of intestinal dysbiosis in Parkinson’s disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/probiotic-correction-of-intestinal-dysbiosis-inparkinsons-disease/.

22. Ermolenko E. I., Milyukhina I. V., Tsapieva A. N., et al. Method of reducing manifestation of non-motor symptoms in patients with parkinson’s disease. Patent RU2734718C1, 2019. (In Russ.)

23. Ermolenko E.I., Kotyleva M. P., Bui Thi Lan An, et al. Research of the intestinal microbiota of residents of Vietnam and Russia. Journal of Tropical Science and Technology. 2016; 12:24–35. ISSN: 0866–753512.

24. Ermolenko E. I., Erofeev N. P., Zacharova L. B., et al. Features of microbiota content and intestinal motility after the correction of experimental dysbiosis with probiotic and autoprobiotic enterococci. Experimental and Clinical Gastroenterology. 2017; (7):89–96. (In Russ.)

25. Ermolenko E., Gromova L., Borschev Yu., et al. Influence of different probiotic lactic Acid bacteria on microbiota and metabolism of rats with dysbiosis. Biosci Microbiota Food Health. 2013; 32(2):41–9. doi:10.12938/bmfh.32.41.

26. Saulnier D. M., Riehle K., Mistretta T., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011; 141(5):1782–91. doi:10.1053/j.gastro.2011.06.072.

27. Zheng J., Wittouck S., Salvetti E., et al. A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leucono stocaceae. Int J Syst Evol Microbiol. 2020; 70(4):2782–2858. doi:10.1099/ijsem.0.004107.

28. Suvorov A., Karaseva A., Kotyleva M., et al. Auto probiotics as an Approach for Restoration of Personalised Microbiota. Front Microbiol. 2018; 9:1869. doi:10.3389/fmicb.2018.01869.

29. Le Chatelier E., Nielsen T., Qin J., Prift i E., Hildebrand F., Falony G., Almeida M., Arumugam M., Batto J. M., Kennedy S., Leonard P., Li J., Burgdorf K., Grarup N., Jørgensen T., Brandslund I., Nielsen H. B., Juncker A. S., Bertalan M., Levenez F., Pons N., Rasmussen S., Sunagawa S., Tap J., Tims S., Zoetendal E. G., Brunak S., Clément K., Doré J., Kleerebezem M., Kristiansen K., Renault P., Sicheritz-Ponten T., de Vos W. M., Zucker J. D., Raes J., Hansen T.; MetaHIT consortium, Bork P., Wang J., Ehrlich S. D., Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013; 500(7464):541–6. doi:10.1038/nature12506.

30. Duncan S. H., Hold G. L., Barcenilla A., Stewart C. S., Flint H. J. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol. 2002; 52(Pt 5):1615–1620. doi:10.1099/00207713–52–5–1615.

31. Marchesi J. R., Dutilh B. E., Hall N., Peters W. H., Roelofs R., Boleij A., Tjalsma H. Towards the human colorectal cancer microbiome. PLoS One. 2011; 6(5): e20447. doi:10.1371/journal.pone.0020447.

32. Rajilić-Stojanović M., Jonkers D. M., Salonen A., et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015; 110(2):278–87. doi:10.1038/ajg.2014.427.

33. Vakhitov T. Ia., Sitkin S. I. [The superorganism concept in biology and medicine]. Eksp Klin Gastroenterol. 2014; 107(7):72–85. PMID:25842410. (In Russ.)

34. Bernalier A., Willems A., Leclerc M., Rochet V., Collins M. D. Ruminococcus hydrogenotrophicus sp. nov., a new H2/CO2-utilizing acetogenic bacterium isolated from human feces. Arch Microbiol. 1996; 166(3):176–83. doi:10.1007/s002030050373.

35. Rey F. E., Faith J. J., Bain J., Muehlbauer M. J., Stevens R. D., Newgard C. B., Gordon J. I. Dissecting the in vivo metabolic potential of two human gut acetogens. J Biol Chem. 2010; 285(29):22082–90. doi:10.1074/jbc.M110.117713.

36. Ushkalova E. A. The Role of Probiotics in Gastroenterology. Pharmateka. 2007; 6:18–25. (In Russ.)

37. Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008; 32(2):147–52. doi:10.1016/j.gcb.2007.06.001.

38. Enck P., Zimmermann K., Menke G., Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol. 2009; 47(2):209–14. doi:10.1055/s-2008–1027702.

39. Kajander K., Myllyluoma E., Rajilic-Stojanovic M., et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Th er. 2008; 27(1):48–57. doi:10.1111/j.1365–2036.2007.03542.x.

40.